ReviewReproductive biology and endocrinology : RB&E2025
The role of programmed cell death in diabetes mellitus-induced erectile dysfunction: from mechanisms to targeted therapy.
Review in Reproductive biology and endocrinology : RB&E, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Research Progress on Programmed Cell Death in Ischemic Stroke and Intervention with Chinese Medicine.Chinese journal of integrative medicine · 2026Review
- ICNPReports (MDPI) · 2026Article
- CircPBX1 ameliorates metabolic memory-associated erectile dysfunction via miR-195-5p/YAP1-mediated angiogenesis in diabetic rats.Communications biology · 2026Article
- Combined Zinc and Metformin Attenuated Impairment of Corpus Cavernosum Function, Imbalance of Zinc Homeostasis, Apoptosis, and Fibrosis in STZ-Induced Diabetic Mice by Inhibiting the TGF-β1/Smad3 Pathway.Biological trace element research · 2026Article
- Exploring the impact of endocrine-disrupting chemicals on erectile dysfunction through network toxicology and machine learning.BMC pharmacology & toxicology · 2025Article
- The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?Biomolecules · 2025Review
- Metabolic Syndrome-Associated Erectile Dysfunction: Multiple Vascular Endothelial Dysfunction Mechanisms and Potential Therapeutic Targets.International journal of biological sciences · 2025Review
- Current status and advances in adipose-derived stem cells therapy for diabetes mellitus erectile dysfunction.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Diabetes mellitus (DM) is a chronic metabolic disease that often leads to vascular endothelial injury and peripheral neuropathy. Erectile dysfunction (ED), a common condition in andrology, is frequently associated with DM. The incidence of diabetes mellitus-induced ED (DMED) is second only to the cardiovascular complications of diabetes. Compared to other types of ED, DMED presents with more severe symptoms, rapid progression, and notable resistance to phosphodiesterase type 5 inhibitors (PDE5is). Various forms of programmed cell death (PCD)-including apoptosis, autophagy, pyroptosis, and ferroptosis-play pivotal roles in the pathogenesis of DMED. An exacerbation of DMED is linked to critical irritants like advanced glycation end-products (AGEs) and reactive oxygen species (ROS) in the corpus cavernosum tissue. These irritants can spark anomalous activations of diverse PCDs, which damage primary corpus cavernosum cells like cavernous nerve cells, endothelial cells, and myocytes, leading to ED. Hence, we reviewed current knowledge on the mechanisms and therapeutic potential of targeting PCDs in DMED, aiming to advance strategies for enhancing erectile function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.